Skip to Content
You are currently on the new version of our website. Access the old version .
CellsCells
  • Review
  • Open Access

22 November 2020

22 Pages

Neurohormonal Modulation as a Therapeutic Target in Pulmonary Hypertension

,
,
and
1
Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain
2
Hospital Universitario Quirónsalud Madrid, UEM, 28223 Madrid, Spain
3
Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares, 28029 Madrid, Spain
4
Institut Clínic Cardiovascular-Hospital Clínic, IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain
This article belongs to the Special Issue Advances in Adrenergic Receptor Biology

Abstract

The autonomic nervous system (ANS) and renin-angiotensin-aldosterone system (RAAS) are involved in many cardiovascular disorders, including pulmonary hypertension (PH). The current review focuses on the role of the ANS and RAAS activation in PH and updated evidence of potential therapies targeting both systems in this condition, particularly in Groups 1 and 2. State of the art knowledge in preclinical and clinical use of pharmacologic drugs (beta-blockers, beta-three adrenoceptor agonists, or renin-angiotensin-aldosterone signaling drugs) and invasive procedures, such as pulmonary artery denervation, is provided.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.